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Introduction
Vasospasm (VSP) is one of the major causes for prolonged
neurologic deficit in patients with aneurysmal subarachnoid
hemorrhage.1 Treatment of VSP is therefore one of the main
priorities for these patients. Balloon angioplasty or stenting
are options for VSP of the proximal vessels, whereas distally
located VSP is preferably treated pharmacologically.2 A long
list of pharmacologic agents has been tested for their effect on
VSP. Intravenous (IV) or oral application of nimodipine com-
bined with triple H therapy (hypertension, hypervolemia,
hemodilution) is currently recommended as the first-line
prevention for VSP.3 In patients not responding to this pre-
ventive therapy, short local intra-arterial nimodipine admin-
istration (SLINA) is recommended, although it is often only
effective during the time of infusion.4However, intra-arterial
(IA) nimodipine administration may be prolonged for a few
days. Few case series have reported about the feasibility,
efficacy, and safety of this treatment, and standardized guide-
lines are lacking.5–8
We report our experience with continuous local intra-
arterial nimodipine administration (CLINA) via a catheter in
the internal carotid artery (ICA) in refractory cerebral VSP.
Case Report
A 40-year-old woman was referred to our hospital due to
headache and nausea that started acutely the day of admis-
sion. She had no history of hypertension or other diseases but
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showed a subarachnoid hemorrhage (SAH) extending to the
suprasellar cisterns and both Sylvian fissures (modified Fisher
grade 4). The Hunt &Hess gradewas 2, and the Glasgow Coma
Scale and the World Federation of Neurosurgery grade were
15 and 1, respectively. CT angiography (CTA) revealed a
saccular aneurysm of the anterior communicating artery
(ACom) (►Fig. 1). The patient had an anatomical variant
with three small ACom segments. The aneurysm was located
at the most distal ACom segment, at the origin of the left
anterior cerebral artery A2 segment (►Fig. 1).
The aneurysm was successfully treated by coil emboliza-
tion, and the patient was asymptomatic after the procedure.
According to the department’s standard post-SAH treatment
protocol, the patient was given continuous IV nimodipine,
fluids, and statins. At day 6, the patient developed hemi-
paresis predominantly affecting the right arm and severe
expressive aphasia corresponding to a National Institute of
Health Stroke Scale (NIHSS) score of 6 (facial palsy 1; arm 2;
leg 1, aphasia 2). CTA showed VSP in the intracranial ICA, the
anterior cerebral artery proximal segment (A1), and the
middle cerebral artery proximal segment (M1) bilaterally,
but predominantly on the left side. VSP was present also in
the basilar artery and the left posterior cerebral artery. At day
7, 30-minute IA administration of 4 mg nimodipine in the left
intracranial ICA and 30 minute IA administration of 4 mg
nimodipine in the left intracranial vertebral artery led to a
clear improvement of angiographic VSP and neurologic im-
pairment. Due to the recurrence of symptoms at day 8,
30-minute IA administration of 4 mg nimodipine in the left
intracranial ICA and in the left intracranial vertebral artery
were repeatedwith beneficial but transitory effect. At day 9, 1
hour IA administration of 8 mg nimodipine followed by
3-minute IA administration of 30 mg papaverine were per-
formed. Digital subtraction angiography (DSA) showed par-
tial resolution of VSP in the left M1 and A1 but persistent VSP
in the left M2 and A2 (►Fig. 2).
Transcranial color-coded sonography (TCCS)measurements
of blood flow velocity in the left distal M1 showed no changes
before and after IA treatment (►Fig. 3). Two hours later,
cerebral MRI showed multiple watershed infarcts in the left
carotid artery territory and in the left parietal lobe (►Fig. 4).
The patient was quickly referred to TCCS that showed
marked worsening of hemodynamics (mean velocity of
300 cm/s in the left distal M1, Lindegaard index > 7). DSA
was therefore repeated and confirmed severe VSP in the left
M1 and A1. CLINA was established by introducing a micro-
catheter (Progreat 2.7F, Terumo Interventional System, Tokyo,
Japan) into the left ICA through a guiding catheter. With the
microcatheter in place, the guiding catheter was pulled back
into the aortic arch. Nimodipine dose was set at 2 mg/h. An IV
bolus dose of 5000 IE heparin was administered initially,
followed by 1500 to 2500 units/h to keep the activated clotting
time >200 s.
A few hours later, the patient showed improvement of
symptoms with normalized motor function and only a slight
residual aphasia (NIHSS ¼ 1). Atday10, TCCS showedadramatic
improvement of the hemodynamic parameters (►Fig. 3).
At day 12, CLINAwas stopped, the catheter and the sheath
were removed, and the full dosage (2 mg/h) was given IV for
7 days and then orally for another 7 days. In addition to
nimodipine, advanced VSP treatment including pressor, flu-
ids, statins, magnesium, and dantrolene was administered.
During the hospital stay a lumbar drainwas inserted due to
transient hydrocephalus, and antibiotics were given due to a
urinary tract infection. No other complications were reported.
The patient was discharged at day 22 and transferred to a local
Fig. 1 (A) Three-dimensional angiography of left carotid artery
showing an anterior communicating artery aneurysmmeasuring 3  7
mm. (B) The aneurysm was completely occluded after coiling. No
vasospasm was seen.
Fig. 2 Left carotid angiogram at the initiation of continuous local intra-arterial (IA) nimodipine infusion day 9 (three short local IA nimodipine
administrations were done on days 7, 8, and 9 after coil embolization). (A) Severe vasospasm is seen in the A1, A2, and M2 branches. (B) Partial
resolution after 4 mg nimodipine in 30 minutes but still severe vasospasm in A2.
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hospital. She had no measurable speech impairment but a
slight disturbance offinemotor skills in the right hand, and she
complained about gait instability and dysesthesia in the right
hemibody (NIHSS ¼ 0). At follow-up day 90, the patient
reported reduced stamina, mild headache, and non–drug-
demanding neuropathic pain in the right arm. Motor function
was normalized, and she had no apparent speech impairment
(NIHSS ¼ 0).Modified Rankin Scale scorewas 2, and Extended
Glasgow Outcome Scale was 5. TCCS showed normal blood
flow velocities in all intracranial arteries, and MRI showed no
new ischemic lesions.
Discussion
This is the first case of continuous local intra-arterial nimo-
dipine administration (CLINA) for refractory VSP described in
Scandinavia. The treatment had a dramatic effect on both
angiographic VSP and neurologic impairment with no com-
plications. In linewith earlier reports,5–10 our case shows that
CLINA is feasible, safe, and may be effective in patients with
symptomatic medically refractory VSP following SAH.
However, there is no consensus when to start the
treatment. Although other reports recommend starting
CLINA if 30-minute IA nimodipine administration does
not show improvement of VSP, the threshold for referring
patients to DSA is not always specified. In some earlier
reports, patients were referred to DSA either after a decline
in the parameters of multimodal neuromonitoring or after
progressive loss of consciousness postoperatively.5,7,8 In
another report, the patients underwent DSAwithin the first
2 hours after onset of clinical symptoms and decrease in
brain tissue oxygen.6 In our patient, CLINA was started
2 days after the first focal neurologic impairment. The two
SLINAs performed at day 7 and day 8 showed good angio-
graphic response and partial clinical improvement. The
third SLINA showed partial resolution of angiographic
VSP with no clinical and Doppler response, andMRI showed
established cerebral infarction. In an earlier study, 21 of 25
patients treated with CLINA developed cerebral infarction
secondary to VSP,7 and, similarly to our case, the mean
onset of CLINA was 9.19  3.31 days. In another case series
of 6 patients, onset of CLINAwas 7.5  2.06 days, and none
of the patients had cerebral infarction.6
Due to the possibly high safety profile and efficacy of the
treatment, it may therefore be appropriate to refer patients
promptly to DSA and CLINA in case of development of focal
neurologic impairment6 to prevent ischemic complications.
Transcranial ultrasound has a high specificity (99%) and
positive predictive value (97%) for the detection of VSP in
the middle cerebral artery11 and is of established value in the
detection and monitoring of VSP after SAH (strong recom-
mendation, class I–II evidence).12,13 In our case, there was a
good correlation between ultrasonographic findings, clinical
impairment, and DSA. Future studies should investigate if
TCCS may play a major role in the early selection of patients
who will benefit from this treatment.
CLINA has some limitations. There are no standardized
guidelines for patient selection, the start and the duration of
CLINA, as well as for the dosage of nimodipine and heparin.
Fig. 3 Mean velocity in the left distal M1 segment measured with transcranial color-coded sonography.
Fig. 4 Diffusion-weighted magnetic resonance imaging day 9 showed
scattered cortical infarctions in the left hemisphere.
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CLINA is an expensive and resource-demanding procedure
requiring specialized intensive care with a multidisciplinary
team of anesthesiologists, neuroradiologists, neurosurgeons,
and the availability of multimodal neurologic monitoring. Wall
dissection, catheter dislocation, sepsis, air emboli, and embolic
infarction due to thrombotic adhesion at catheter or vessel wall
are all potential complications of CLINA. Moreover, a too high
nimodipine dose may lead to hypotension, whereas inappropri-
ate heparin dosage may lead to either thromboembolic or
hemorrhagic complications. None of the earlier studies has
reported complications.5–8 However, there are no conclusive
data about the safetyof CLINAbecause all the current evidence is
based on case series that may be affected by publication bias.
In conclusion, our case report adds new evidence on the
feasibility, safety, and efficacy of CLINA. Further studies are
needed to clarify if transcranial ultrasound or other modali-
ties such as MR and/or CT perfusion are able to early select
which patients are likely to profit from CLINA.
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